BCDA · Insider Trading
BioCardia, Inc. Common Stock
Every open-market purchase and sale reported by BCDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Peter Altman | President and CEO | Buy | +500 | +$475 |
| 2026-09-30 | Peter Altman | President and CEO | Buy | +1,000 | +$1.03K |
| 2026-09-23 | Peter Altman | President and CEO | Buy | +1,900 | +$2.00K |
| 2026-09-04 | Peter Altman | President and CEO | Buy | +800 | +$872 |
| 2026-08-18 | Peter Altman | President and CEO | Buy | +5,400 | +$5.02K |
| 2026-08-13 | Peter Altman | President and CEO | Buy | +1,900 | +$1.75K |
| 2026-07-29 | Peter Altman | President and CEO | Buy | +5,000 | +$3.90K |
| 2026-07-20 | Peter Altman | President and CEO | Buy | +500 | +$415 |
| 2026-07-15 | Peter Altman | President and CEO | Buy | +4,300 | +$3.75K |
| 2026-07-10 | Peter Altman | President and CEO | Buy | +7,500 | +$7.17K |
| 2026-07-08 | Peter Altman | President and CEO | Buy | +5,400 | +$5.21K |
| 2026-07-07 | David McClung | Chief Financial Officer | F | −23,125 | −$28.68K |
| 2026-07-07 | Jay M Moyes | Director | A | +8,000 deriv. | — |
| 2026-07-07 | Andrew Scott Blank | Director | A | +8,000 deriv. | — |
| 2026-07-07 | Bill Facteau | Director | A | +8,000 deriv. | — |
| 2026-07-07 | Marvin Slosman | Director | A | +8,000 deriv. | — |
| 2026-07-07 | Edward M Gillis | Senior Vice President, Devices | F | −17,269 | −$21.41K |
| 2026-07-07 | Peter Altman | President and CEO | F | −54,606 | −$67.71K |
| 2026-07-07 | Jim L. Allen | Director | A | +8,000 deriv. | — |
| 2026-07-07 | Simon H Stertzer | Director | A | +8,000 deriv. | — |
| 2026-07-01 | Peter Altman | President and CEO | A | +110,625 | +$132.75K |
| 2026-07-01 | Edward M Gillis | Senior Vice President, Devices | A | +39,521 | +$47.43K |
| 2026-07-01 | David McClung | Chief Financial Officer | A | +60,483 | +$72.58K |
| 2026-06-24 | Simon H Stertzer | Director | Buy | +109,200 | +$103.58K |
| 2026-06-22 | Peter Altman | President and CEO | Buy | +2,300 | +$2.04K |
| 2026-06-09 | Peter Altman | President and CEO | Buy | +5,000 | +$4.25K |
| 2026-05-21 | Peter Altman | President and CEO | Buy | +1,700 | +$1.57K |
| 2026-05-18 | Peter Altman | President and CEO | Buy | +5,700 | +$5.24K |
| 2026-05-15 | Peter Altman | President and CEO | Buy | +5,100 | +$5.20K |
| 2026-04-29 | Peter Altman | President and CEO | Buy | +5,000 | +$5.55K |
| 2026-04-22 | Peter Altman | President and CEO | Buy | +1,000 | +$1.23K |
| 2026-03-26 | Peter Altman | President and CEO | Buy | +900 | +$1.11K |
| 2026-02-04 | Peter Altman | President and CEO | Buy | +5,000 | +$5.65K |
| 2026-01-21 | Peter Altman | President and CEO | Buy | +900 | +$1.19K |
| 2025-12-17 | Peter Altman | President and CEO | Buy | +1,100 | +$1.44K |
| 2025-12-10 | Andrew Scott Blank | Director | A | +12,000 deriv. | — |
| 2025-12-10 | Jim L. Allen | Director | A | +12,000 deriv. | — |
| 2025-12-10 | Peter Altman | President and CEO | MIXED | +163,072 | +$223.41K |
| 2025-12-10 | David McClung | Chief Financial Officer | MIXED | +87,615 | +$120.03K |
| 2025-12-10 | Marvin Slosman | Director | A | +12,000 deriv. | — |
| 2025-12-10 | Bill Facteau | Director | A | +12,000 deriv. | — |
| 2025-12-10 | Simon H Stertzer | Director | A | +12,000 deriv. | — |
| 2025-12-10 | Edward M Gillis | Senior Vice President, Devices | MIXED | +53,250 | +$72.95K |
| 2025-12-10 | Jay M Moyes | Director | A | +12,000 deriv. | — |
| 2025-09-23 | Andrew Scott Blank | Director | Buy | +288,000 | +$360.00K |
| 2025-09-23 | Peter Altman | President and CEO | Buy | +48,000 | +$60.00K |
| 2025-09-23 | Simon H Stertzer | Director | Buy | +398,400 | +$498.00K |
| 2025-08-25 | Peter Altman | President and CEO | Buy | +700 | +$1.28K |
| 2025-08-13 | Peter Altman | President and CEO | Buy | +100 | +$183 |
| 2025-08-12 | Peter Altman | President and CEO | Buy | +400 | +$700 |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Simon H Stertzer | Director | 718,392 | $647.63K |
| Andrew Scott Blank | Director | 636,058 | $573.41K |
| Peter Altman | President and CEO | 385,085 | $347.15K |
| David McClung | Chief Financial Officer | 114,245 | $102.99K |
| Jim L. Allen | Director | 109,667 | $98.86K |
| Edward M Gillis | Senior Vice President, Devices | 54,126 | $48.79K |
| Richard M Krasno | Director | 16,268 | $14.67K |
| Bill Facteau | Director | 13,123 | $11.83K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCDA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.